Select Bibliography

Filter by any of these (after searching):

NCCTG-N0577

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 2 items

CODEL: Phase III study of RT alone, RT plus temozolomide, or temozolomide alone for newly diagnosed 1P/19Q codeleted anaplastic oligodendroglioma patients. Updated analysis from the initial study design (NCCTG N0577, Alliance)

Jaeckle, Kurt A. , Ballman, Karla V. , van den Bent, Martin ... - SNO - Neuro-oncology - 2020

Abstract - Primary - Other - Neuro-Onc - NCCTG-N0577

CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III randomized study of RT vs. RT+TMZ vs. TMZ for newly diagnosed 1p/19q-codeleted anaplastic glioma. Analysis of patients treated on the original protocol design

Jaeckle, Kurt , Vogelbaum, Michael , Ballman, Karla ... - AAN - Neurology - 2016

Abstract - Primary - Other - Neuro-Onc - NCCTG-N0577